专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US10544187B2 Targeting regulatory T cells with heterodimeric proteins 有权
公开(公告)号：US10544187B2
公开(公告)日：2020-01-28
申请号：US14217166
申请日：2014-03-17
申请人： Xencor, Inc.
发明人： Seung Chu , Matthew Bernett , Dilki Wickramarachchi , John Desjarlais
IPC分类号： C12P21/08 , A61K9/00 , C07K1/18 , C07K16/28 , C07K14/55
摘要： The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.

22. 发明授权

US10457737B2 Engineered immunoglobulin Fc polypeptides displaying improved complement activation 有权
公开(公告)号：US10457737B2
公开(公告)日：2019-10-29
申请号：US15019395
申请日：2016-02-09
申请人： Research Development Foundation
发明人： George Georgiou , Chang-Han Lee
IPC分类号： C07K16/00 , C12P21/08 , C07K16/28 , C07K1/00 , A61K39/00
摘要： Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain are provided. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds C1q, and optionally activating Fc receptors, but that is significantly reduced for binding to the inhibitory FcγRIIb receptor. Furthermore, methods and compositions are provided for promoting complement dependent cytotoxicity (CDC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or a different non-Fc binding domain.

23. 发明授权

US10441665B2 Liquid formulation of long acting insulinotropic peptide conjugate 有权
公开(公告)号：US10441665B2
公开(公告)日：2019-10-15
申请号：US15714556
申请日：2017-09-25
申请人： HANMI PHARM. CO., LTD.
发明人： Hyun Uk Kim , Hyung Kyu Lim , Sung Hee Hong , Dae Jin Kim , Sung Min Bae , Se Chang Kwon
IPC分类号： A61K39/00 , A61K38/26 , C07K16/00 , C12P21/08 , A61K47/68 , C07K16/42 , C07K16/28 , C07K16/06 , A61K9/08 , C07K14/575 , C07K14/605 , A61K47/26 , A61K39/395 , C07K19/00 , G01N33/50
摘要： Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.

24. 发明授权

US10400040B2 Anti-GITR antibodies 有权
公开(公告)号：US10400040B2
公开(公告)日：2019-09-03
申请号：US15625307
申请日：2017-06-16
申请人： Merck Sharp & Dohme Corp.
发明人： Xiao Min Schebye , Grigori P. Ermakov , Douglas J. Hodges , Leonard G. Presta
IPC分类号： A61K39/395 , C12P21/08 , C07H21/04 , C07K16/00 , C07K16/28 , A61K39/00
摘要： Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.

25. 发明授权

US10357472B2 Homogenous antibody drug conjugates via enzymatic methods 有权
公开(公告)号：US10357472B2
公开(公告)日：2019-07-23
申请号：US15317907
申请日：2015-06-11
申请人： CSPC Dophen Corporation
发明人： Sean Hu , Lisha Allen
IPC分类号： A61K39/00 , C07K16/00 , C12P21/08 , A61K31/255 , C07K16/30 , C07K16/32 , C07K16/28 , C12N9/10 , A61K47/68
摘要： The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.

26. 发明授权

US10336825B2 Antibody binding to FcRn for treating autoimmune diseases 有权
公开(公告)号：US10336825B2
公开(公告)日：2019-07-02
申请号：US15480264
申请日：2017-04-05
申请人： HANALL BIOPHARMA CO., LTD.
发明人： Sung Wuk Kim , Seung Kook Park , Jae Kap Jeong , Hyea Kyung Ahn , Min Sun Kim , Eun Sun Kim , Hae-Young Yong , Dongok Shin , Yeon Jung Song , Tae Hyoung Yoo
IPC分类号： C07K16/00 , C12P21/08 , C07K16/28 , G01N33/68 , G01N33/566 , C07K1/00 , A61K39/00
摘要： The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

27. 发明授权

US10294301B2 Anti-human BDCA-2 antibody 有权
公开(公告)号：US10294301B2
公开(公告)日：2019-05-21
申请号：US15107660
申请日：2014-12-22
申请人： Astellas Pharma Inc.
发明人： Shinsuke Nakao , Masayuki Ito , Yoshiyuki Tenda
IPC分类号： C12P21/08 , C07K16/00 , C07K16/28
摘要： [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.[Means for Solution] The present inventors have investigated anti-human BDCA-2 antibodies, and as a result, they have provided an anti-human BDCA-2 antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 109 of SEQ ID NO: 4, a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 6 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 8, and a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 122 of SEQ ID NO: 10 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 12.

28. 发明授权

US10294286B2 Chimeric inhibitor molecules of complement activation 有权
公开(公告)号：US10294286B2
公开(公告)日：2019-05-21
申请号：US15400412
申请日：2017-01-06
申请人： Rigshospitalet , Kobenhavns Universitet , Syddansk Universitet
发明人： Peter Garred , Tina Hummelshoj Glue , Mikkel-Ole Skjodt
IPC分类号： A61K38/36 , A61K38/00 , A61P7/08 , A61K38/14 , A61K35/14 , A61K38/16 , C07K1/00 , C07K14/00 , C07K16/00 , C07K17/00 , C12P21/08 , C07K14/47 , A61K38/17 , A61K45/06 , C07K14/705 , C07K14/81
摘要： The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.

29. 发明授权

US10293049B2 Etanercept formulations stabilized with amino acids 有权
公开(公告)号：US10293049B2
公开(公告)日：2019-05-21
申请号：US13654735
申请日：2012-10-18
申请人： Coherus Biosciences, Inc.
发明人： Mark Manning , Brian Murphy
IPC分类号： A61K39/00 , C07K1/00 , C12P21/08 , A61K47/26 , A61K39/395 , C07K14/715 , A61K47/10 , A61K9/16 , C07K14/705 , A61K38/17 , A61K38/19 , A61K9/14 , A61K9/00 , A61K9/08 , A61K47/18 , A61P29/00 , A61P19/02 , A61P17/06
摘要： The invention provides stabilized aqueous pharmaceutical etanercept compositions stabilized with an amino acid and suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

30. 发明授权

US10246514B2 Single domain antibodies that bind to human CD20 有权
公开(公告)号：US10246514B2
公开(公告)日：2019-04-02
申请号：US15701530
申请日：2017-09-12
申请人： The United States of America, as represented by the Secretary of the Navy
发明人： Jinny Lin Liu , Daniel Zabetakis , Ellen R. Goldman , George P. Anderson
IPC分类号： C12P21/08 , C07K16/00 , C07K16/28 , A61K38/17 , A61K39/395 , A61K39/00
摘要： Described herein is the development of recombinant single domain antibodies, also known as nanobodies, that may provide better therapeutic results or be useful for diagnostic applications of B-cell lymphomas, or in other applications where an antibody to CD20 may be useful.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式